ORAMED PHARMACEUTICALS INC. — Income Charts
25 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
Cost of Revenue
$0
Gross Profit
$0
R&D↑+36.1% +$527K
$2M
D&A↓-3.2% -$1K
$30K
Operating Income↑+21.4% +$662K
$-2M
EBITDA↓-3.2% -$1K
$30K
Interest Expense↓-100.0% -$1M
$0
Other Income/Expense↑+501.3% +$77M
$62M
Pretax Income
$10M
Tax Provision↑+876.3% +$10M
$11M
Net Income
$10M
Gross Margin
0.7%
Operating Margin
-225.0%
Net Margin
-382.1%
Effective Tax Rate↑+24.7pts
18.6%
Deferred Tax Liabilities
$8M
ETR (Continuing Operations)
15.0%
ETR Federal Statutory↑+0.0pts
21.0%
Operating Lease Cost
—
Revenue YoY Variation↓-100.0pts
-100.0%
Income YoY Variation↑+28.2pts
21.4%
Revenue QoQ Variation
-100.0%
Income QoQ Variation↑+1.0pts
2.5%